Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2013 2
2015 1
2016 2
2017 2
2019 7
2020 10
2021 7
2022 6
2023 6
2024 5
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Do patients benefit from omega-3 fatty acids?
Sherratt SCR, Mason RP, Libby P, Steg PG, Bhatt DL. Sherratt SCR, et al. Cardiovasc Res. 2024 Feb 17;119(18):2884-2901. doi: 10.1093/cvr/cvad188. Cardiovasc Res. 2024. PMID: 38252923 Free PMC article. Review.
However, as observed in JELIS, REDUCE-IT, and RESPECT-EPA, EPA-only formulations significantly reduce CVD events in high-risk patients. ...In vitro and in vivo studies have shown different effects of EPA compared with DHA alone or EPA …
However, as observed in JELIS, REDUCE-IT, and RESPECT-EPA, EPA-only formulations significantly reduce CVD events …
Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason RP, Sherratt SCR, Eckel RH. Mason RP, et al. Best Pract Res Clin Endocrinol Metab. 2023 May;37(3):101681. doi: 10.1016/j.beem.2022.101681. Epub 2022 Jun 3. Best Pract Res Clin Endocrinol Metab. 2023. PMID: 35739003 Free article. Review.
Omega-3 fatty acids (n3-FAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower TG levels, but their ability to reduce CV risk has been highly inconsistent. Trials using icosapent ethyl (IPE), a purified EPA ethyl ester, produced …
Omega-3 fatty acids (n3-FAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower TG levels, but th …
Triglyceride Lowering Drugs.
Feingold KR. Feingold KR. 2026 Apr 23. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2026 Apr 23. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 28402615 Free Books & Documents. Review.
LDL-C may increase with EPA + DHA when the TG levels are markedly elevated (>500mg/dL). EPA alone does not increase LDL-C. ...Numerous studies of low dose omega-3-fatty acids on cardiovascular outcomes have failed to demonstrate a benefit. However, in the …
LDL-C may increase with EPA + DHA when the TG levels are markedly elevated (>500mg/dL). EPA alone does not increase …
Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
Hernandez P, Passi N, Modarressi T, Kulkarni V, Soni M, Burke F, Bajaj A, Soffer D. Hernandez P, et al. Curr Atheroscler Rep. 2021 Sep 13;23(11):72. doi: 10.1007/s11883-021-00962-z. Curr Atheroscler Rep. 2021. PMID: 34515873 Free PMC article. Review.
However, treatment with eicosapentaenoic acid (EPA) combined with docosahexanoic acid (DHA) did not reduce ASCVD in a similar population studied in the STRENGTH trial. ...Residual ASCVD risk in individuals treated with contemporary care may be due in part to non-LDL …
However, treatment with eicosapentaenoic acid (EPA) combined with docosahexanoic acid (DHA) did not reduce ASCVD in a similar …
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Skulas-Ray AC, et al. Circulation. 2019 Sep 17;140(12):e673-e691. doi: 10.1161/CIR.0000000000000709. Epub 2019 Aug 19. Circulation. 2019. PMID: 31422671 Free article.
Since 2002, prescription agents containing EPA+DHA or EPA alone have been approved by the US Food and Drug Administration for treating very high triglycerides; these agents are also widely used for hypertriglyceridemia. ...The results of a trial of 4 g/d pres …
Since 2002, prescription agents containing EPA+DHA or EPA alone have been approved by the US Food and Drug Administrati …
Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved.
Watanabe Y, Tatsuno I. Watanabe Y, et al. J Atheroscler Thromb. 2020 Mar 1;27(3):183-198. doi: 10.5551/jat.50658. Epub 2019 Oct 3. J Atheroscler Thromb. 2020. PMID: 31582621 Free PMC article. Review.
Findings of these studies have led to the development of omega-3 PUFA preparations for the treatment of dyslipidemia, including a highly purified eicosapentaenoic acid (EPA)-ethyl ester product (Epadel( )) in Japan and an EPA/docosahexaenoic acid (DHA) prepar …
Findings of these studies have led to the development of omega-3 PUFA preparations for the treatment of dyslipidemia, including a highly pur …
Differentiating EPA from EPA/DHA in cardiovascular risk reduction.
Toth PP, Chapman MJ, Parhofer KG, Nelson JR. Toth PP, et al. Am Heart J Plus. 2022 May 28;17:100148. doi: 10.1016/j.ahjo.2022.100148. eCollection 2022 May. Am Heart J Plus. 2022. PMID: 38559888 Free PMC article. Review.
Attained plasma levels of EPA may be an important determinant of efficacy, with a substudy of REDUCE-IT suggesting that the threshold for clinical benefit of EPA is approximately 100 mug/mL, a level achieved in only a minority of patients in other stud …
Attained plasma levels of EPA may be an important determinant of efficacy, with a substudy of REDUCE-IT suggesting that …
Icosapent ethyl: From the REDUCE-IT trial to clinical practice.
Pedro-Botet J. Pedro-Botet J. Clin Investig Arterioscler. 2025 Jun;37 Suppl 1:500820. doi: 10.1016/j.arteri.2025.500820. Epub 2025 Jun 3. Clin Investig Arterioscler. 2025. PMID: 40467382 Free article. Review. English, Spanish.
Although mild/moderate hypertriglyceridemia is a recognized vascular risk factor, only two studies, the Japan EPA Lipid Intervention (JELIS) and the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT), using pure eicosapenta …
Although mild/moderate hypertriglyceridemia is a recognized vascular risk factor, only two studies, the Japan EPA Lipid Intervention …
DHA, RvD1, RvD5, and MaR1 reduce human coronary arteries contractions induced by PGE(2).
Bouhadoun A, Manikpurage HD, Deschildre C, Zalghout S, Dubourdeau M, Urbach V, Ho-Tin-Noe B, Deschamps L, Michel JB, Longrois D, Norel X. Bouhadoun A, et al. Prostaglandins Other Lipid Mediat. 2023 Apr;165:106700. doi: 10.1016/j.prostaglandins.2022.106700. Epub 2022 Dec 15. Prostaglandins Other Lipid Mediat. 2023. PMID: 36528331 Review.
They could increase vascular contraction while EPA and DHA could reduce it. Studies have been mostly conducted on animal vessels. Therefore, the aim of the study was to investigate if EPA, DHA, and DHA-derived metabolites: RvD1, Rv …
They could increase vascular contraction while EPA and DHA could reduce it. Studies have been mostly conducted o …
Unraveling the discrepancies between REDUCE-IT and STRENGTH trials with omega-3 fatty acids: new analytical approaches.
Zhang W, Gan D, Huo S, Chen P. Zhang W, et al. Front Nutr. 2024 Dec 19;11:1490953. doi: 10.3389/fnut.2024.1490953. eCollection 2024. Front Nutr. 2024. PMID: 39758310 Free PMC article. Review.
Both trials aimed to evaluate the effects of prolonged administration of nutritional lipids, specifically omega-3 fatty acids, on major adverse cardiovascular events (MACEs) in high-risk patients undergoing statin therapy. REDUCE-IT used eicosapentaenoic acid (EP …
Both trials aimed to evaluate the effects of prolonged administration of nutritional lipids, specifically omega-3 fatty acids, on major adve …
44 results